azacitidine has been researched along with Fatigue in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Beach, CL; Bernal, T; Braverman, J; Döhner, H; Dombret, H; Dong, Q; Guo, S; Jang, JH; La Torre, I; Liesveld, J; Martens, UM; Mayer, J; Nehme, SA; Pocock, C; Ravandi, F; Roboz, GJ; Selleslag, D; Shi, L; Skikne, B; Wang, MC; Wei, AH; Yu, P | 1 |
| Busija, L; Kenealy, M; McQuilten, ZK; Seymour, JF; Stanworth, S; Weinkove, R; Wood, EM | 1 |
| Becerra, C; Conkling, P; Dong, Q; Kellerman, A; Kingsley, EC; Kolibaba, K; Laille, E; Morris, JC; Rifkin, RM; Savona, MR; Skikne, BS; Ukrainskyj, SM | 1 |
| Cinalli, T; Colaluca, K; Duong, HK; Rogers, HJ; Saunthararajah, Y; Sekeres, MA; Stein, BL; Tabarroki, A; Tiu, RV; Visconte, V | 1 |
| Dey, BR; Hasserjian, RP; Spitzer, TR | 1 |
| Steensma, DP; Stone, RM | 1 |
| Cogle, C; Garcia-Manero, G; Giordano, H; Gore, SD; Jabbour, E; Kantarjian, H; Laille, E; Macbeth, KJ; Sakoian, S; Shi, T; Skikne, B; Ward, R | 1 |
| Martínez-Francés, A | 1 |
| Franco Osorio, R; Martínez-Francés, A; Mercadal Vilchez, S; San Miguel Amigo, L | 1 |
| Bauman, J; Belinsky, S; Fekrazad, M; Jones, D; Lee, SJ; Muller, C; Ravindranathan, M; Rutledge, T; Verschraegen, C | 1 |
| Abdel-Wahab, O; Berube, C; Coutre, S; Gallegos, L; Gotlib, JR; Greenberg, P; Levine, R; Liedtke, M; Medeiros, BC; Mitchell, BS; Pollyea, DA; Zehnder, J; Zhang, B | 1 |
| Aribi, A; Cortes, J; Davisson, J; Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, HM; O'Brien, S; Ravandi, F; Shan, J | 1 |
| Blum, W; Byrd, JC; Chan, KK; Devine, H; Devine, SM; Grever, MR; Hackanson, B; Heerema, NA; Huynh, L; Kefauver, C; Klisovic, RB; Liu, S; Liu, Z; Lozanski, G; Marcucci, G; Murgo, A; Plass, C; Vukosavljevic, T | 1 |
3 review(s) available for azacitidine and Fatigue
| Article | Year |
|---|---|
Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes.
Topics: Aged; Antibiotic Prophylaxis; Antifungal Agents; Azacitidine; Clinical Trials as Topic; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Drug Administration Schedule; Enzyme Inhibitors; Epigenesis, Genetic; Fatigue; Gastrointestinal Diseases; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Injections, Subcutaneous; Mucositis; Myelodysplastic Syndromes; Pancytopenia; Patient Selection | 2010 |
Adverse effects of azacitidine: onset, duration, and treatment.
Topics: Age of Onset; Antimetabolites, Antineoplastic; Azacitidine; Disease Management; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Fatigue; Gastrointestinal Diseases; Humans; Maximum Tolerated Dose; Myelodysplastic Syndromes; Neutropenia; Prognosis; Survival Rate | 2011 |
Azacitidine adverse effects in patients with myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Fatigue; Gastrointestinal Diseases; Humans; Maximum Tolerated Dose; Myelodysplastic Syndromes; Neutropenia; Prognosis; Quality-Adjusted Life Years; Survival Rate | 2011 |
7 trial(s) available for azacitidine and Fatigue
| Article | Year |
|---|---|
Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial.
Topics: Azacitidine; Fatigue; Humans; Leukemia, Myeloid, Acute; Quality of Life; Remission Induction; Treatment Outcome | 2021 |
Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Fatigue; Female; Food; Food-Drug Interactions; Gastric Acidity Determination; Gastrointestinal Diseases; Hematologic Diseases; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Proton Pump Inhibitors | 2018 |
Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites; Antimetabolites, Antineoplastic; Azacitidine; Biological Availability; DNA Methylation; Fatigue; Female; Gastrointestinal Diseases; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Chronic; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Neutropenia | 2011 |
A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Conjunctivitis; Diarrhea; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Fatigue; Female; Humans; Male; Middle Aged; Nausea; Neoplasms; Quinazolines; Treatment Outcome | 2012 |
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; fms-Like Tyrosine Kinase 3; Humans; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Myeloid; Male; Middle Aged; Mutation; Nausea; Nuclear Proteins; Nucleophosmin; Prognosis; Remission Induction; Thalidomide; Treatment Outcome; Vomiting | 2013 |
Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 7; Decitabine; Drug Administration Schedule; Fatigue; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Prognosis; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome; Vomiting | 2007 |
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Brain Diseases; Decitabine; Fatigue; Humans; Infections; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Neutropenia; Remission Induction; Treatment Failure; Valproic Acid | 2007 |
3 other study(ies) available for azacitidine and Fatigue
| Article | Year |
|---|---|
Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Dyspnea; Fatigue; Hemoglobins; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life | 2022 |
Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; DNA Modification Methylases; Fatigue; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nitriles; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Remission Induction; Treatment Outcome | 2015 |
Case records of the Massachusetts General Hospital. Case 28-2009. A 68-year-old man with fatigue, cough, and peripheral-blood monocytosis.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Bone Marrow Examination; Combined Modality Therapy; Cough; Decitabine; Diagnosis, Differential; Fatigue; Humans; Leukemia, Myeloid, Acute; Leukocytosis; Male; Monocytes; Stem Cell Transplantation | 2009 |